India’s pharma regulatory landscape is expanding beyond manufacturing compliance, with new developments targeting medicine pricing, sterile-drug quality, medical marketing, and obesity treatment.
Drug development faces mounting safety concerns, clinical setbacks, and pressure to modernize standards. Three industry moves reveal how pharma balances risk management with faster, more efficient development.
In an exclusive interaction with Thiruamuthan, Assistant Editor at India Pharma Outlook, Pushkar Kulkarni, General Manager, Johnson & Johnson Innovative Medicine, India & South Asia, discusses how technology, AI, genomics and precision medicine are s
HPV shot before pregnancy may cut preterm birth risk, adding another potential benefit to established cancer prevention.
India’s biopharma leap is gaining momentum as peptides and ADCs drive investment, advanced therapeutics, precision diagnostics and manufacturing growth.
India’s Drug Pricing Architecture is evolving as regulators expand price controls, compliance rules, and reforms to improve medicine affordability.
Pharma giants are locking in drug discovery platforms, oral small molecules, radiopharmaceuticals, and manufacturing networks to strengthen future pipelines.
Severe headache, fever, confusion, and neck stiffness can signal meningitis. On World Meningitis Day 2026, experts explain warning signs and when urgent medical care is needed.
Lixudebart is CSL and Alentis USD 1.6 billion bet on claudin-1, spanning rare kidney diseases and the unmet treatment need in PSC.
Cancer care is entering a new phase as blood-based detection and drug combinations create new paths for earlier diagnosis and stronger treatment.
.jpg)
, CDSCO.jpg)
